Eysz

eyszlab.com

Eysz is developing a digital health platform that measures disease progression, intervention efficacy, and side effects to assist clinicians in developing a personalized care plan for neurological diseases. Doctors currently rely on patient self-reported data and subjective clinical exams to manage and treat chronic neurological disorders. The lack of a reliable biomarker in neurological disease leads to economic burdens of $1.7T in the US and Europe alone and stagnant patient outcomes with no significant improvement in outcomes in the last 30 years. Eysz is using analysis of eye movements as a biomarker to assess brain health across neurological disorders, starting with epilepsy – a disorder characterized by recurrent seizures. After completing a successful clinical study sponsored by the NIH and NSF, Eysz will be releasing their first product to diagnose and monitor childhood absence epilepsy in Q3 2023.